Search, Find and Buy Antibodies, ELISA Kits and Proteins.
Loading Loading
Order hotline:
phone +1 404 474 4654
fax +1 888 205 9894 (TF)
Details for Product No. ABIN500805

Tumor Necrosis Factor (Ligand) Superfamily, Member 11 (TNFSF11) (Center) antibody

Request
Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms ODF, OPGL, sOdf, CD254, OPTB2, RANKL, TRANCE, hRANKL2, Ly109l, OPG, Trance, TNFSF11
Epitope
»Alternatives Center
Reactivity
»Alternatives Human, Mouse (Murine), Rat (Rattus)
Host
»Alternatives Rabbit
Clonality Polyclonal
Conjugate
»Alternatives Un-conjugated
Application
»Alternatives ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
Pubmed 4 references available
Catalog no. ABIN500805
Quantity 0.1 mg
Price
390.50 $   Plus shipping costs $45.00
Shipping to
Availability Will be delivered in 6 to 8 Business Days
Immunogen sRANK-L antibody was raised against a 14 amino acid peptide from near the center of Human sRANK-L.
Isotype IgG
Specificity This antibody detects CD254 / RANKL. It will recognize both the soluble form and the uncleaved transmembrane form of RANK-L.
Purification Immunoaffinity Chromatography
Alternative Name CD254 / RANKL
Background The receptor activator of NF-kappaB ligand (RANK-L) is a recently discovered member of the TNF-ligand family involved in the regulation of the T cell-dependent immune response, lymph node organogenesis and bone formation. RANK-L exists as both a normal, transmembrane form and a truncated, soluble form (sRANK-L), both of which can stimulate the receptor. Activation of T cells, such as by treatment with interleukin-7, induces RANK-L production and leads to an increase of osteoclast formation and bone loss. Finally, sRANK- L can activate the antiapoptotic kinase Akt through a signaling complex involving Src kinase and TRAF6, suggesting sRANK-L may also play a role in regulating apoptosis.
Alternate names: ODF, OPGL, Osteoclast differentiation factor, Osteoprotegerin ligand, RANK Ligand, RANKL, Receptor activator of nuclear factor kappa B ligand, TNF-related activation-induced cytokine, TNFSF11, TRANCE, Tumor necrosis factor ligand superfamily member 11
Gene ID 8600
NCBI Accession NP_003692
Application Notes ELISA. Western blot: 0.25 – 0.5 μg/ml. Immunohistochemistry on paraffin sections. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Concentration 1.0 mg/mL
Buffer PBS, 0.02% Sodium azide
Preservative Sodium azide
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Expiry Date 12 months
Background publications Wong, Rho, Arron et al.: "TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells." in: The Journal of biological chemistry, Vol. 272, Issue 40, pp. 25190-4, 1997 (PubMed).

Kong, Yoshida, Sarosi et al.: "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis." in: Nature, Vol. 397, Issue 6717, pp. 315-23, 1999 (PubMed).

Weitzmann, Cenci, Rifas et al.: "Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines." in: Blood, Vol. 96, Issue 5, pp. 1873-8, 2000 (PubMed).

Bharti, Takada, Shishodia et al.: "Evidence that receptor activator of nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism." in: The Journal of biological chemistry, Vol. 279, Issue 7, pp. 6065-76, 2004 (PubMed).

Alternatives for antigen "Tumor Necrosis Factor (Ligand) Superfamily, Member 11 (TNFSF11)", type "Antibodies"
Hosts (98), (27), (22), (11)
Reactivities (114), (96), (29), (25), (15), (1)
Applications (120), (74), (42), (24), (20), (18), (9), (8), (5), (4), (4), (3), (2), (2), (2), (2), (2), (1)
Conjugates (25), (8), (3), (3), (2), (2), (2), (2), (2), (2), (2), (2)
Epitopes (14), (8), (8), (4), (3), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1)
Beacon